Table 1.
No AMS | AMS | |||
---|---|---|---|---|
3400 m | 4300 m | 3400 m | 4300 m | |
n (%) | 472 (89) | 315 (87) | 56 (11) | 48 (13) |
Male, n (%) | 284 (60) | 193 (61) | 25 (45)a | 24 (50) |
SBP (mm Hg) | 128 (118–138) | 128 (118–138) | 128 (116–138) | 128 (118–139) |
DBP (mm Hg) | 82 (81–83) | 83 (82–84) | 82 (80–84) | 84 (81–86) |
HR (beats-min−1) | 84 (82–85) | 82 (80–83) | 87 (84–90) | 86 (82–89) |
SpO2 (%) | 90 (88–93) | 87 (84–89) | 90 (88–92) | 85 (81–88)b |
Preexisting hypertension, n (%) | 41 (98) | 24 (96) | l (2)c | 1 (2) |
Acetazolamide, n (%) | 61 (13) | 49 (16) | 6 (11) | 8 (16) |
Ibuprofen, n (%) | 28 (6) | 19 (6) | 6 (11) | 5 (10) |
Rate of ascent (range) (nights) | 1 (0–3) | 3 (1–5) | 1 (0–3) | 3 (1–5) |
Values are means (95% confidence intervals) unless noted otherwise.
Lower vs women (P=0.03).
Lower in those with acute mountain sickness (P=0.02).
Lower vs participants without preexisting hypertension (P=0.04).